BioSpace News Archive

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility.

LeMaitre, a provider of vascular devices, implants and services, reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

Neurocrine Biosciences, Inc. will present at the Bank of America Securities 2023 Healthcare Conference at 10:00 a.m. Pacific Time on Tuesday, May 9, 2023.

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, announced the Company’s first quarter financial results will be released after market close on Wednesday, May 10, 2023.

Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.

Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.

Penumbra, Inc., a global healthcare company focused on innovative therapies, reported financial results for the first quarter ended March 31, 2023.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced that it will host its first quarter 2023 operating and financial results webcast on Tuesday, May 9, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Astria Therapeutics, Inc. granted stock options to purchase 12,000 shares of Astria’s common stock on May 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

ENDRA Life Sciences Inc. announced the closing of its previously announced underwritten public offering of 4,312,500 shares of its common stock and warrants to purchase 2,156,250 shares of its common stock, which included the exercise in full by the underwriter of its option to purchase 562,500 additional shares of ENDRA’s common stock and additional warrants to purchase 281,250 shares of common stock.